Doctor showing tablet to patient. Management of metastatic renal cell carcinoma should be highly individualized, according to investigators. Preoperative systemic therapy does not lead to worse ...

AUSTIN, Texas -- Cytoreductive nephrectomy improved overall survival (OS) by more than a year for patients with metastatic renal cell carcinoma (mRCC) with sarcomatoid or rhabdoid (S/R) ...

Cytoreductive nephrectomy merits further consideration in appropriately risk-stratified, surgically fit patients with mRCC.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Pretreatment with sunitinib followed by ...

A Canadian study recently assessed 709 patients with intermediate- and high-risk synchronous mRCC with or without sarcomatoid features. Most patients had clear cell histology and were treated with ...

Researchers writing in JAMA Network Open report that for patients with metastatic clear cell renal cell carcinoma, removing the kidney and its primary tumor is not associated with improved overall ...

Thirty-five percent of patients who received targeted therapy for renal cell carcinoma underwent cytoreductive nephrectomy, according to the results of retrospective study. The addition of ...

Metastatic renal cell carcinoma (RCC) has traditionally been associated with a poor prognosis with few effective treatments. In the multimodal treatment of metastatic RCC, cytoreductive nephrectomy ...

Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy The following represents disclosure information provided by authors of this manuscript. All ...

Renal cell carcinoma (RCC) represents the 15th most common cancer worldwide. About 20% of patients with renal cell carcinoma eventually develop liver metastasis (LM). Furthermore, the liver is the ...

Although retrospective data supported a similar survival benefit for cytoreductive nephrectomy in the targeted therapy era as it did for the initial immunotherapy era (1992 to 2006), level 1 evidence ...